Compare TTGT & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTGT | STRO |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | United States | United States |
| Employees | N/A | 131 |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.4M | 338.9M |
| IPO Year | 2024 | N/A |
| Metric | TTGT | STRO |
|---|---|---|
| Price | $5.99 | $37.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $10.75 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 511.6K | 252.7K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $2.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.41 | $0.67 |
| 52 Week High | $9.00 | $39.74 |
| Indicator | TTGT | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 71.70 | 70.73 |
| Support Level | $5.44 | $31.61 |
| Resistance Level | $6.43 | N/A |
| Average True Range (ATR) | 0.37 | 2.93 |
| MACD | 0.07 | 0.15 |
| Stochastic Oscillator | 87.56 | 79.36 |
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. The company provides marketing and sales services that deliver business impact for enterprise technology companies. It develops editorial content across multiple technology-focused websites and channels to engage audiences researching information technology solutions. The company generates revenue by providing market insight and market access to the technology market, including enterprise technology, artificial intelligence, channel, cybersecurity, media & entertainment, and service providers. Geographically, it derives the majority of revenue from North America.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.